Company announcement – No. 42 / 2022
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
Copenhagen, DK and Boston, MA, September 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology firm centered on the invention and improvement of modern peptide-based medicines, in accordance with part 32 of the Danish Capital Markets Act, declares the whole number of shares and voting rights in the Company on the finish of a calendar month throughout which there have been modifications to its share capital.
In Company announcement No. 39/2022 from September 13, 2022, Zealand introduced a rise in share capital regarding train of worker warrants. Following this announcement, the desk under lists the whole number of shares and voting rights in Zealand as much as and together with September 30, 2022.
|
Date |
Number of shares (nominal worth of DKK 1 every) |
Share capital (nominal worth in DKK) |
Number of voting rights |
| August 31, 2022 | 46,538,186 | 46,538,186 | 46,538,186 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology firm centered on the invention and improvement of peptide-based medicines. More than 10 drug candidates invented by Zealand have superior into medical improvement, of which two have reached the market and three candidates are in late-stage improvement. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create alternatives for extra sufferers to probably profit from Zealand-invented peptide investigational brokers at present in improvement.
Zealand was based in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that features Boston. For extra details about Zealand’s business and actions, please go to www.zealandpharma.com.
Forward-Looking Statement
The above data accommodates forward-looking statements that present Zealand Pharma’s expectations or forecasts of future occasions, together with forward-looking statements in regards to the termination of the Company’s ADR program. Such forward-looking statements are topic to dangers, uncertainties and inaccurate assumptions, which can trigger precise outcomes to vary materially from expectations set forth herein and might trigger all or any of such forward-looking statements to be incorrect. If all or any of such forward-looking statements show to be incorrect, our precise outcomes may differ materially and adversely from these anticipated or implied by such statements. All such forward-looking statements converse solely as of the date of this launch and are based mostly on data out there to Zealand Pharma as of the date of this launch. Except as required by regulation, the Company assumes no obligation to replace these forward-looking statements publicly.
Contact:
| Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: [email protected] David Rosen (U.S. Media) |
